On this page
Daxxify
daxibotulinumtoxinA-lanm
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Daxxify
Proper name
daxibotulinumtoxinA-lanm
Licence type
351(a)
BLA number
761127
Applicant
Revance Therapeutics, Inc.
Center
CDER
Presentations
2
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 100UNITS | For Injection | Intramuscular | Single-Dose Vial | Rx | September 7, 2022 |
| 50UNITS | For Injection | Intramuscular | Single-Dose Vial | Rx | September 7, 2022 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |